Discovery Labs Announces Proposed Public Offering of Common Stock
March 15 2012 - 4:01PM
Discovery Laboratories, Inc. (Nasdaq:DSCO) today
announced that it is offering to sell shares of its common stock in
an underwritten public offering.
The Company also expects to grant the underwriters a 30-day
option to purchase additional shares of common stock to cover
over-allotments, if any. Lazard Capital Markets LLC is acting
as the sole book-running manager for the offering, Stifel Nicolaus
Weisel is acting as co-lead manager, and ROTH Capital Partners, LLC
is acting as co-manager. While the offering is expected to
price before 9:30 am EDT on March 16, 2012, the offering is subject
to market conditions, and there can be no assurance as to whether
or when the offering may be completed, or as to the actual size or
terms of the offering.
The securities are being offered by Discovery Laboratories, Inc.
pursuant to a registration statement previously filed and declared
effective by the Securities and Exchange Commission. The securities
may be offered only by means of a prospectus, including a
prospectus supplement, forming a part of the effective registration
statement. When available, copies of the preliminary prospectus
supplement, the final prospectus supplement and the accompanying
base prospectus relating to this offering may be obtained at the
Securities and Exchange Commission web site at http://www.sec.gov,
or from Lazard Capital Markets LLC, 30 Rockefeller Plaza, 60th
Floor, New York, NY 10020 or via telephone at (800) 542-0970.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any securities of Discovery
Laboratories, Inc. nor shall there be any sale of these securities
in any state or jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under
the securities laws of any such state or jurisdiction.
About Discovery Labs
Discovery Laboratories, Inc. is a specialty biotechnology
company developing its novel proprietary KL4 surfactant technology
that produces a synthetic, peptide-containing surfactant that is
structurally similar to pulmonary surfactant and is being developed
in liquid, lyophilized, and aerosolized dosage forms. Surfactants
are produced naturally in the lungs and are essential for
breathing. Discovery Labs is also developing its proprietary
drug delivery technologies to enable efficient delivery of
aerosolized KL4 surfactant and other inhaled therapies.
Forward-Looking Statements
To the extent that statements in this press release are not
strictly historical, all such statements are forward-looking, and
are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. These
forward-looking statements are subject to certain risks and
uncertainties that could cause actual results to differ materially
from the statements made. Examples of such risks and
uncertainties, including those related to Discovery Labs'
securities offering and its development programs, are described in
Discovery Labs' filings with the Securities and Exchange Commission
including the most recent reports on Forms 10-K, 10-Q and 8-K, and
any amendments thereto.
CONTACT: John G. Cooper, President and Chief Financial Officer
215-488-9490
Discovery labs (NASDAQ:DSCO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Discovery labs (NASDAQ:DSCO)
Historical Stock Chart
From Oct 2023 to Oct 2024